AKYLA/ Financials
MarketsScreenerFinancialsResearchChat
Equity / BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Bio-Techne Corp.
XNAS · usd
SIC 2836 · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
FIGI BBG001S66C28
72.55▼ 0.07 (-0.10%)
As of 2026-10-23
Price / Volume
Valuation
Market Cap
Enterprise Value
Trailing P/E
Price / Sales
EV / Revenue
EV / EBITDA
Financial Highlights
Revenue (TTM)
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
Net Debt
Trading Information
Previous Close
72.62
Day's Range
72.55 – 72.63
52-Week Range
43.20 – 72.69
Volume
1.9M
Avg Volume
3.0M
Share Statistics
Shares Outstanding
Employees
3,100
Exchange
XNAS
Listed
1989-05-08
Share count as of August 17, 2026

Bio-Techne Corp. (TECH) Financial Statements

View
Income Statement
Detail
Standard
Period
Quarterly
Loading Income Statement…
Key questions about Bio-Techne Corp. (TECH)
What is Bio-Techne Corp.'s Market Cap?
Bio-Techne Corp.'s Market Cap is $11.4B, based on as-reported figures from SEC (XBRL) filings.
What is Bio-Techne Corp.'s Enterprise Value?
Bio-Techne Corp.'s Enterprise Value is $11.3B, based on as-reported figures from SEC (XBRL) filings.
What is Bio-Techne Corp.'s Trailing P/E?
Bio-Techne Corp.'s Trailing P/E is 62.6×, based on as-reported figures from SEC (XBRL) filings.
What is Bio-Techne Corp.'s Price / Sales?
Bio-Techne Corp.'s Price / Sales is 9.4×, based on as-reported figures from SEC (XBRL) filings.
What is Bio-Techne Corp.'s EV / Revenue?
Bio-Techne Corp.'s EV / Revenue is 9.3×, based on as-reported figures from SEC (XBRL) filings.
What is Bio-Techne Corp.'s EV / EBITDA?
Bio-Techne Corp.'s EV / EBITDA is 32.4×, based on as-reported figures from SEC (XBRL) filings.
What is Bio-Techne Corp.'s Revenue (TTM)?
Bio-Techne Corp.'s Revenue (TTM) is $1.2B, based on as-reported figures from SEC (XBRL) filings.
What is Bio-Techne Corp.'s Net Income (TTM)?
Bio-Techne Corp.'s Net Income (TTM) is $181.9M, based on as-reported figures from SEC (XBRL) filings.
What is Bio-Techne Corp.'s EBITDA?
Bio-Techne Corp.'s EBITDA is $349.2M, based on as-reported figures from SEC (XBRL) filings.
What is Bio-Techne Corp.'s Diluted EPS (TTM)?
Bio-Techne Corp.'s Diluted EPS (TTM) is 1.16, based on as-reported figures from SEC (XBRL) filings.
Akyla / Financials · TECHAs-filed SEC (XBRL) data
Showing the most recent year. Subscribe for full statement history.
Income Statement(in millions of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022
CONSOLIDATED STATEMENTS OF EARNINGS AND COMPREHENSIVE INCOME
Net sales
YoY growth+1.3%-1.5%-0.4%-1.0%
Cost of sales
Gross margin
% of revenue65.8%66.9%64.6%65.6%
Operating expenses:
Selling, general and administrative
Research and development
Total operating expenses
% of revenue42.7%42.6%46.2%49.0%
Operating income
% of revenue23.1%24.2%18.4%16.6%
Other income (expense):
Total other income (expense), net
Earnings before income taxes
Income taxes
Net earnings
% of revenue17.0%16.4%12.8%13.3%
Other comprehensive income (loss):
Foreign currency translation income (loss)
Unrealized losses on derivative instruments
Other comprehensive income (loss)
Comprehensive income
Earnings per share:
Basic (in dollars per share)
Diluted (in dollars per share)